Mauna Kea Technologies Identifies 'Triple Healing' as Predictor of Sustained Ulcerative Colitis Remission

Event summary

  • Mauna Kea Technologies published a study in the UEG Journal identifying 'triple healing' as a new therapeutic target for ulcerative colitis, assessed via Cellvizio®.
  • The study followed 81 UC patients in remission over 24 months, with 0% relapse rate among those achieving 'triple healing' compared to 33% in others.
  • Cellvizio®'s confocal laser endomicroscopy outperformed conventional endoscopy, histology, and biomarkers in predicting relapse.
  • The findings build on over a decade of independent research across 430+ patients, reinforcing Cellvizio®'s role in IBD management.
  • Mauna Kea plans to engage with medical societies and payers to establish a dedicated reimbursement pathway for IBD monitoring.

The big picture

The study underscores the growing role of advanced imaging in managing inflammatory bowel disease (IBD), a market exceeding $25 billion annually. Conventional endoscopy often fails to detect subclinical inflammation and barrier dysfunction, leading to relapse in one-third of patients. Cellvizio®'s ability to predict sustained remission positions it as a key tool in personalizing IBD treatment and optimizing therapeutic strategies.

What we're watching

Clinical Adoption
The pace at which 'triple healing' is integrated into clinical guidelines and routine practice will determine Cellvizio®'s market penetration.
Reimbursement Pathway
Whether Mauna Kea can secure dedicated reimbursement for IBD monitoring will be critical for broader adoption.
Therapeutic Development
How pharmaceutical developers leverage Cellvizio® for patient stratification in clinical trials could expand its utility.